Favipiravir treatment started 2 days post-infection provided a highly significant level of protection (7/9 survivors; 78%) compared to the placebo group (1/9 survivors; 11%), and performed better than ribavirin (3/9 survivors; 33%) ( Figure 3A ).
← all excerpts
Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever.
1
—
—